Skip to main content

Table 2 Comparative analysis between SoJIA children which were treated every 2 and every 4 weeks

From: Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Parameters Q2W (n =11) Q4W (n =26) р
Data of baseline
Hemoglobin, g/dl 9.8 (8.16; 11.6) 11,4 (10,8; 13,0) 0,006
Anemia, n (%) 9 (81.8) 12 (46,2) 0,07*
WBC, *109/l 17.2 (12.8; 20.8) 9,85 (7,8; 13,8) 0,008
WBC in 1 week, *109/l 11.6 (8.2; 19.0) 7.6 (5.2; 11.9) 0.05
Granulocytes, cells in 1 μl 13728 (10112; 18654) 6445 (4914; 8787) 0,002
Granulocytes in 1 week, cells 1 μl 8944 (6560; 15390) 3314 (1840; 7240) 0,005
Granulocytes in 2 weeks, cells 1 μl 8925 (7700; 10332) 3408 (2907; 3975) 0.01
CRP, mg/l 100.0 (20.6; 120.0) 18.0 (10.3; 74.5) 0.01
ESR, mm/h 46.0 (42.0; 63.0) 25.5 (12.0; 50.0) 0.01
Ferritin, mg/ml 1287.0 (326.0; 3509.0) 128.0 (51.0; 224.0) 0.0006
LDH, U/l 714.0 (635.0; 796.0) 464.0 (423.0; 513.0) 0.006
Total protein, g/dl 6.7 (6.2; 7.0) 7.2 (6.8; 7.8) 0.004
Albumin, g/dl 2.1 (1.8; 2.5) 3.1 (2.9; 3.3) 0.0003
Hepatomegaly 10 (90.9) 10 (38.5) 0.003
Splenomegaly 6 (54.6) 5 (19.2) 0.05
Lymphadenopathy 5 (45.5) 8 (30.8) 0.47
Coagulopathy 4 (36.3) 0 (0.0) 0.005*
Interstitial lung disease 5 (45.5) 1 (3.9) 0.005*
Heart involvement 6 (54.6) 4 (15,4) 0.04*
CNS dysfunction 6 (54.6) 0 (0.0) 0.0001*
MAS before TCZ (any time point) 7 (63.6) 5 (19.2) 0.018*
MAS immediately precede TCZ 5 (45.5)*** 0 (0.0) 0.001*
Outcomes during TCZ course
Corticosteroids discontinuation, n (%) 2/7 (28.6) 19/19 (100.0) 0.0001*
Corticosteroids discontinuation, days 167.0 (94.0; 237.0) 62.0 (34.0; 93.0) 0.005
Methotrexate discontinuation, due to remission of SoJIA, n (%) 1/8 (12.5) 8/24 (33.3) 0.39*
Cyclosporine A discontinuation, n (%) 3/7 (42.9) 8/13 (61.5) 0.64*
SoJIA relapses 5 (45.5) 2 (7.7) 0.016*
MAS during TCZ 5 (45.5)*** 0 (0.0) 0.001*
Inactive disease 0 (0.0) 12/25** (48.0) 0.03*
TCZ-off remission 0 (0.0) 7/25** (28.0) 0.15*
  1. *Fisher’s exact test, **the data analysis was performed on 25 patients (1 withdrew due to infusion reaction), ***the same patients whom TCZ was initiated during the MAS (MAS before TCZ and after)